Genocea Biosciences Inc año OPV
¿Qué es el año OPV de Genocea Biosciences Inc?
El año OPV de Genocea Biosciences Inc es 2014
¿Cuál es la definición de año OPV?
La oferta pública inicial es un tipo de oferta pública en la cual las acciones de una compañía generalmente se venden a inversionistas institucionales que, a su vez, venden al público en general, en una bolsa de valores, por primera vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
año OPV de compañías en Sector Health Care en NASDAQ en comparadas con Genocea Biosciences Inc
¿Qué hace Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Empresas con año opv similar a Genocea Biosciences Inc
- Australian REIT Income Fund tiene año OPV de 2013
- Brookfield Asset Management PRF SH CL A SE37 tiene año OPV de 2013
- Modern Meat tiene año OPV de 2013
- Blue Capital Reinsurance Ltd tiene año OPV de 2013
- Siyata Mobile tiene año OPV de 2013
- Mirati Therapeutics Inc tiene año OPV de 2013
- Genocea Biosciences Inc tiene año OPV de 2014
- Glaukos tiene año OPV de 2015
- UBS ETFs Public - MSCI ACWI SF UCITS ETF tiene año OPV de 2015
- Acasta Enterprises tiene año OPV de 2015
- Faron Pharmaceuticals Oy tiene año OPV de 2015
- GreenPower Motor Co tiene año OPV de 2015
- Sunrun Inc tiene año OPV de 2015